Moleculin Biotech
MBRX
22 hedge funds and large institutions have $2.91M invested in Moleculin Biotech in 2023 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 1 reducing their positions, and 4 closing their positions.
500% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 1
0% more funds holding
Funds holding: 22 → 22 (0)
0% more ownership
Funds ownership: 0.03% → 0.03% (+0%)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
8% less capital invested
Capital invested by funds: $3.17M → $2.91M (-$266K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Squarepoint
New York
|
+$28K |
| 2 |
HF
HRT Financial
New York
|
+$18.4K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$18K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$15.8K |
| 5 |
Renaissance Technologies
New York
|
+$14.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Charles Schwab
San Francisco,
California
|
-$38.8K |
| 2 |
SCM
Sio Capital Management
New York
|
-$30.2K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$11.9K |
| 4 |
Rockefeller Capital Management
New York
|
-$1K |
| 5 |
CA
Clearstead Advisors
Cleveland,
Ohio
|
-$636 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Rockefeller Capital Management
New York
| – | -$1K | -5 | Closed |
|
|
CA
27
Clearstead Advisors
Cleveland,
Ohio
| – | -$636 | -2 | Closed |
|
|
GRP
28
Global Retirement Partners
San Rafael,
California
| – | -$178 | – | – |
|
MBRX Hedge Fund Activity: Q1 2023 in Review
22 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q1 2023, worth a combined $2.91M — down 8.4% from $3.17M a quarter earlier.
Fund positioning in MBRX was balanced in Q1 2023: 4 funds opened new positions, 4 closed out, 6 added to existing stakes and 1 trimmed.
The largest buyer was Squarepoint, opening a new position worth an estimated $28K. The largest seller was Charles Schwab, exiting entirely with an estimated $38.8K sold.
- 22 institutional investors held Moleculin Biotech (MBRX) as of Q1 2023, unchanged from Q4 2022.
- Funds reported $2.91M of Moleculin Biotech stock for Q1 2023, down 8.4% quarter-over-quarter.
- 4 funds opened new Moleculin Biotech positions in Q1 2023 and 4 closed out, a net change of 0 holders.
- The largest Moleculin Biotech buyer in Q1 2023 was Squarepoint, an estimated $28K added.
- The largest Moleculin Biotech seller in Q1 2023 was Charles Schwab, an estimated $38.8K sold.
Based on aggregated 13F filings for Q1 2023.